Skip to main content
Download PDF
  • Primary research
  • Open access
  • Published:

The mitochondrial C16069T polymorphism, not mitochondrial D310 (D-loop) mononucleotide sequence variations, is associated with bladder cancer

Cancer Cell International volume 13, Article number: 120 (2013) Cite this article

Abstract

Background

Bladder cancer is a relatively common and potentially life-threatening neoplasm that ranks ninth in terms of worldwide cancer incidence. The aim of this study was to determine deletions and sequence variations in the mitochondrial displacement loop (D-loop) region from the blood specimens and tumoral tissues of patients with bladder cancer, compared to adjacent non-tumoral tissues.

Methods

The DNA from blood, tumoral tissues and adjacent non-tumoral tissues of twenty-six patients with bladder cancer and DNA from blood of 504 healthy controls from different ethnicities were investigated to determine sequence variation in the mitochondrial D-loop region using multiplex polymerase chain reaction (PCR), DNA sequencing and southern blotting analysis.

Results

From a total of 110 variations, 48 were reported as new mutations. No deletions were detected in tumoral tissues, adjacent non-tumoral tissues and blood samples from patients. Although the polymorphisms at loci 16189, 16261 and 16311 were not significantly correlated with bladder cancer, the C16069T variation was significantly present in patient samples compared to control samples (p < 0.05). Interestingly, there was no significant difference (p > 0.05) of C variations, including C7TC6, C8TC6, C9TC6 and C10TC6, in D310 mitochondrial DNA between patients and control samples.

Conclusion

Our study suggests that 16069 mitochondrial DNA D-Loop mutations may play a significant role in the etiology of bladder cancer and facilitate the definition of carcinogenesis-related mutations in human cancer.

Introduction

Human mitochondrial DNA (mtDNA) is a 16569-bp closed circular, double-stranded molecule approximately 1000 copies per cell. mtDNA contains 37 genes, including 13 subunits involved in the electron transport chain, 22 tRNAs, the 12S and 16S rRNAs, and a non-coding region (D-loop) located at nucleotide position 16024–576 (MITOMAP, 2011) [1]. The D-loop region regulates the replication and transcription of mtDNA, where mutations in this region might lead to copy number and/or change in mtDNA gene expression [2].

Bladder cancer is the ninth most common cancer worldwide [3]. According to the latest American Cancer Society statistics, bladder cancer accounts for 7% of all cancers and 3% of all cancer deaths [4, 5]. In Iran, bladder cancer accounts for 7.04% of all cancers [6].

Many attempts have been made to develop an urothelial cancer biomarker test to complement or replace urine cytology, including NMP22, BTA stat, BTA TRAK, and FISH. Most studies on the molecular genetics of the bladder cancer focus on changes in genomic DNA, including oncogenes and tumor suppressor genes, such as HRAS, ERBB2, TP53 and RB, and subsequent cellular events [7, 8].

Mitochondrial function and DNA attract less interest in studies on bladder carcinoma. Mitochondrial dysfunction has been linked to a wide range of degenerative and metabolic diseases, cancer, and even aging. mtDNA, which has a very high mutation rate, results in three classes of clinically relevant phenotypes: deleterious germline mtDNA mutations, which are linked to mitochondrial diseases; mtDNA polymorphisms, which are related to environmental adaptation in human evolution; and mtDNA somatic mutations, which are associated with aging and cancer. Mitochondrial defects were first associated with carcinogenesis several decades before, when Warburg reported “injury of the respiratory chain” and high glycolytic rate as typical of cancer [9–12].

Mitochondrial DNA is thought to accumulate more mutations than nuclear DNA (nDNA) to some extent, because the protective histones as well as the highly efficient DNA repair mechanisms do not exist in the mitochondrial nucleus. Certain tumors have been shown to result from mutations in nDNA-encoded mitochondrial proteins, which may result in increased reactive oxygen species (ROS) production. Mitochondrial dysfunction does appear to be a factor in cancer etiology. Alterations in mitochondrial DNA (mtDNA), including point mutations, deletions, insertions and genome copy number changes, are believed to be responsible for carcinogenesis [13–15]. For example, many reports have identified a mtDNA 4977-bp deletion in lung [16], breast [17] and endometrial carcinomas [18].

The use of mtDNA mutation and/or polymorphism patterns as a biomarker is rapidly expanding in disciplines, ranging from rare metabolic diseases and aging to cancer and the tracing of human migration patterns, population characterization and human identification in forensic science. In this study, we examined the presence of mutations in the mitochondrial D-Loop sequences of tumoral tissues as compared with adjacent non-tumoral tissues from Iranian patients with bladder cancer.

Materials and Methods

Twenty-six men with primary urothelial bladder cancer with a mean age of 62.5 years were enrolled in this study (Table 1). The patients’ written consent was obtained and the institutional review board approved this study. Tumoral tissues were obtained from transurethral resection of the bladder tumor (TURBT) or radical cystectomy specimens. Tumoral tissues and adjacent non-tumoral tissues were immediately frozen in liquid nitrogen and kept at -80°C, while blood samples from patients were obtained before surgery.

Table 1 Age and histological type of primary urothelial bladder neoplasm sybtypes
Full size table

Urothelial bladder cancer diagnosis was done via histological analysis. Blood samples from healthy controls with a mean age of 57.5 years were obtained from 404 individuals of 17 ethnicities and 100 random individuals, all from the Tehran Special Medical Center. The exclusion criterion for the control group was any history of cancer, metabolic diseases and mitochondrial DNA related diseases that may affect the mtDNA. Ethics approval and patient informed consent including consent to participate in the study and consent to publish was obtained for the present study in accordance to the Tehran Special Medical Center and Medical Ethics Committee (Approval No. MS-16-2007).

DNA extraction and sequencing

Genomic DNA (DNA fast, QIAGEN, Cat. No. 51204) was isolated from the tumoral tissues, adjacent non-tumoral tissues and blood samples of patients, as well as from the blood samples of controls, according to the manufacturer’s protocol. Two pairs of primers designed to amplify the mtDNA D-loop region are as follows: ONP 98 F )1579-15810(: 5′-ATC ATT GGA CAA GTA GCA TC -3′ and ONP 79R )780-761(: 5′-GAG CTG CAT TGC TGC GTG CT-3′. Polymerase chain reaction (PCR) was carried out with the following protocol: pre-denaturation at 95°C for 5 min, then 35 cycles of 94°C for 30 sec, 60°C for 45 sec and 72°C for 1 min, and a final extension step of 72°C for 6 min. Each amplified fragment was purified using a Agarose Gel DNA Fragment Recovery Kit, Ver.2.0 (TaKaRa, Japan) and subsequently sequenced using a ABI PRISM 3730 sequence analyzer (gene Fanavaran, Macrogene Seoul, Korea). The quality of the obtained chromatograms was assessed by FinchTV® software Version 1.4.0 (Geospiza, Inc., USA).

Multiplex PCR

The PCR reactions were performed for 35 cycles of the following steps: 94°C for 10 min, 55°C for 10 min, and 72°C for 35 sec. Using the primers ONP 86, ONP 89, ONP 10, ONP 74, ONP 25 and ONP 99, the deletion-prone region between 5461 nt of the light strand and 15000 nt of the heavy strand was investigated in all the patients. The distances between the primers were long enough to allow amplification only if a part of the DNA between each respective primers was deleted. As a control in PCR analysis, a normal internal mtDNA fragment in a region which is seldom affected by deletions was amplified using the primer pair of ONP 86 and ONP 89 (Table 2). Polymerase chain reaction products were separated on 2% agarose gels and run in 0.5× Tris/Borate/EDTA buffer at 110 V for 50 min, stained in 0.002 μg/mL ethidium bromide, and visualized by means of an ultraviolet light.

Table 2 Primers used for detection of four deletions
Full size table

Southern blot analysis

Extracted mtDNA was eletrophoresed on 1% agarose gel. After electrophoresis, the DNA were denatured, neutralized and transferred to nylon membrane. Meanwhile, the ONP98 primer (5′-ATCATTGGACAAGTAGCATC-3′), located at 15791–15810 bp, and the ONP79 primer (5′-GAGCTGCATTGCTGCGTGCT-3′), located at 780–761 bp of the mtDNA, were used to amplify a 1558-bp fragment from the D-loop region. This fragment was used as a mtDNA probe. Southern blot analysis was performed using the DIG DNA Labeling and Detection Kit (Cat. #11093657910, Roche).

Statistical analysis

Sequences were edited and aligned using ClustalX. The revised Cambridge Reference Sequence was used as a reference (GI: 251831106) (MITOMAP, 2009). The Chi-square test was used with SPSS (Statistical Package for the Social Sciences, version: 13) to examine the association of variations with control and patient samples. P-values < 0.05 were regarded as statistically significant.

Results

Samples from a total of 26 patients with sporadic bladder cancer were screened for mitochondrial deletions and variations. Sequence analysis found a total of 110 variations (Cambridge Mitochondrial Sequences), of which 62 mutations were previously reported (MITOMAP). However, 48 of these mutations were reported as new mutations, which are summarized in Table 3. In this study, almost all of the variations were homoplasmic, but in 6 (16.6%) cases, a C nucleotide insertion was seen in locus 16194. No mitochondrial deletions were found in the patient samples (Figures 1 and 2), as confirmed by Southern blotting (Figure 3).

Table 3 List of variations in both healthy controls and bladder cancer patients
Full size table
Figure 1
figure 1

Multiplex-PCR amplification. Lanes 1, 2, 3 and 5 show the internal control (279 bp), lane 4 is the negative control and lane M is a 100 bp DNA size marker. No other bands were observed. Amplification only takes place if deletions occur in the DNA between the PCR primers.

Full size image
Figure 2
figure 2

Long range PCR amplification of mtDNA using Phusion Flash high-fidelity PCR Master Mix, Thermo Scientific. A two-step long-range PCR was carried out on the major arc of the mitochondrial genome using the Expand Long Template PCR System to detect mitochondrial deletions. DNA products were separated using a 0.7% agarose gel containing ethidium bromide and viewed under UV light. Lanes 1 and 3: negative control; Lanes 2 and 4: an amplified 11 Kb fragment, indicating no deletions were observed in mtDNA; lane M: 1 kb DNA ladder marker.

Full size image
Figure 3
figure 3

Southern blot analysis of mitochondrial DNA (mtDNA) digested with the restriction enzyme BamH1 (nt14258), and hybridized with a DIG-labeled probe. Lanes 1–5 shows intact mtDNA (~16.6 Kb).

Full size image

Four common variations, 16069, 16189, 16261 and 16311, were found in the tumoral tissues, adjacent non-tumoral tissues and blood samples of both patients and controls from different ethnicities. The polymorphisms at 16189, 16261 and 16311 were not significantly correlated with bladder cancer. However, the D-loop C16069T polymorphism (Figure 4) was significantly correlated with bladder cancer (P < 0.05). Analysis of control samples by ethnicities for these 4 variations is summarized in Table 4. No significant difference (p > 0.05) in D310 C variations was observed between the patient and control samples (Table 5).

Figure 4
figure 4

Chromatogram showing homoplasmy at position 16069 of the mitochondrial DNA D-loop in a normal sequence (Figure4-A) and a variation (Figure4-B). The arrow marks the sequence variations.

Full size image
Table 4 Comparison of 4 common variations in bladder cancer patients and controls
Full size table
Table 5 Association of the mtDNA D310 variation in bladder cancer patients and controls
Full size table

Discussion

Our sequencing analysis focused on the mtDNA D-loop region, which is highly polymorphic and contains two hypervariable regions, HV1 (16024–16383) and HV2 (57–333), that was considered as a somatic mutation “hot spot” in many types of cancer [19]. In this study, no deletions were seen in the mitochondrial genome. One hundred and sixteen variations were observed in the D-Loop region, where 48 of them were not previously reported. Wada et al.[20] also reported that the majority of somatic mutations were homoplasmic, suggesting that the mutant mtDNA became dominant in tumor cells. Fliss et al.[21] screened 14 urinary bladder cancers for somatic mutations in the D-loop region, and found mutations in 4 (29%) samples.

Polymorphism 16189, which is highly polymorphic, was the previous focus of oncological research because carriers with the T16189C polymorphism were apparently more susceptible to breast cancer and ganglioma development. Interestingly, the T16189C polymorphism was found in 14% of endometrial cancers [22] and type II diabetes mellitus [23, 24].

In this study, in contrast to 16189, 16194, 16261 and 16311 variations, the C16069T polymorphism of the D-loop indicated significant correlation with bladder cancer (P < 0.05), which has not been studied in bladder cancer before. However, the C16069T polymorphism has been reported in prostate cancer [25], pancreatic cancer [26], endometrial cancer [27], breast cancer [28, 29], repeated pregnancy loss [30] and age-related macular degeneration [31]. This result supports our hypothesis, which shows the potential of specific mitochondrial 16069 polymorphism involvement in carcinogenesis.

Many studies reported that the C150T polymorphism is correlated with longevity (MITOMAP, 2009). The possible function of the C150T transition was investigated in a previous study [32], suggesting that the C150T transition functions in remodeling mtDNA replication. However, in our study, no significant differences were found between C150T mutations in patients and control samples from different ethnicities.

Large-scale mtDNA deletions have been demonstrated in several cancers. Kamalidehghan et al.[33] found that the common mtDNA4977 deletion was less frequent in gastric cancer tissues compared to the normal adjacent tissues. While in another study, a deletion of approximately 8.9 kb was more frequent in gastric carcinoma tissues than adjacent normal tissue samples [34]. However, in the present study, no deletions were detected in bladder carcinoma tissues nor adjacent non-tumoral tissues. Therefore, the pattern of mitochondrial deletions may differ among different carcinomas.

Marchington et al.[35] first used the term D310 to describe a highly polymorphic mononucleotide tract of poly (C) that varies from 12 to 18 Cs, located between nucleotide positions 303 and 318 in CSB II, that forms a RNA–DNA hybrid known as an R-loop. This poly(C) region is interrupted at nucleotide position 310 by a T (CCCCCCCTCCCCC), in which the number of Cs before the T can vary between 7 to 9 in normal polymorphic variants [35]. D310 has been reported as a mutational hot-spot in a large panel of tumors including gastric, head and neck, breast, colorectal, lung and bladder cancers, where head and neck cancer has the highest rate of D310 variants (37%), followed by breast (29%) and colorectal (28%) cancers. However, no D310 alterations were detected in prostate and ovarian cancers [36, 37].

The D310 region of mtDNA plays an important role in mitochondrial biogenesis, where somatic insertions or deletions of one or two base pairs in this region are thought to have negligible effects on cancers. However, major deletions or insertions of up to ten bases in the D310 region could interfere with mtDNA biogenesis [38]. Mutations in the D-loop, mostly at D310, have been found in 21% of all head and neck squamous cell carcinomas [39]. However, in our study, the D310 mtDNA sequence variations, including C7TC6, C8TC6, C9TC6 and C10TC6, were not significantly different (p > 0.05) between bladder cancer patients and controls of different ethnicities.

In conclusion, our study suggests that the mitochondrial DNA D-Loop 16069 mutation may play a significant role in the etiology of bladder cancer and facilitate the definition of carcinogenesis-related mutations in human mtDNA.

Competing of interests

The authors declare that they have no competing of interests.

Abbreviations

mtDNA:

mitochondrial DNA

D-Loop:

Displacement loop

PCR:

Polymerase chain reaction

nDNA:

nuclear DNA

ROS:

Reactive oxygen species

TURBT:

Transurethral resection of the bladder tumor

SPSS:

Statistical package for the social sciences

HV:

Hypervariable

mtMSI:

Mitochondrial microsatellite instability.

References

  1. Suzuki M, Toyooka S, Miyajima K, Iizasa T, Fujisawa T, Bekele NB, Gazdar AF: Alterations in the mitochondrial displacement loop in lung cancers. Clin Cancer Res. 2003, 9 (15): 5636-5641.

    CAS  PubMed  Google Scholar 

  2. Yu M, Zhou Y, Shi Y, Ning L, Yang Y, Wei X, Zhang N, Hao X, Niu R: Reduced mitochondrial DNA copy number is correlated with tumor progression and prognosis in Chinese breast cancer patients. IUBMB life. 2007, 59 (7): 450-457. 10.1080/15216540701509955.

    Article  CAS  PubMed  Google Scholar 

  3. Tomera KM: NMP22 BladderChek Test: point-of-care technology with life-and money-saving potential. Expert Rev Mol Diagn. 2004, 4 (6): 783-794. 10.1586/14737159.4.6.783.

    Article  PubMed  Google Scholar 

  4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58 (2): 71-96. 10.3322/CA.2007.0010.

    Article  PubMed  Google Scholar 

  5. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007, 18 (3): 581-

    Article  CAS  PubMed  Google Scholar 

  6. Shakhssalim N, Hosseini SY, Basiri A, Eshrati B, Mazaheri M, Soleimanirahbar A: Prominent bladder cancer risk factors in Iran. Asian Pac J Cancer Prev. 2010, 11: 601-606.

    PubMed  Google Scholar 

  7. Ørntoft TF, Wolf H: Molecular alterations in bladder cancer. Urol Res. 1998, 26 (4): 223-233. 10.1007/s002400050050.

    Article  PubMed  Google Scholar 

  8. Brandau S, Böhle A: Bladder cancer. Eur Urol. 2001, 39 (5): 491-497. 10.1159/000052494.

    Article  CAS  PubMed  Google Scholar 

  9. Warburg O: On the origin of cancer cells. Science. 1956, 123 (3191): 309-314. 10.1126/science.123.3191.309.

    Article  CAS  PubMed  Google Scholar 

  10. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, Mey A, Taschner PEM, Rubinstein WS, Myers EN: Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000, 287 (5454): 848-10.1126/science.287.5454.848.

    Article  CAS  PubMed  Google Scholar 

  11. Gambhir SS: Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002, 2 (9): 683-693. 10.1038/nrc882.

    Article  CAS  PubMed  Google Scholar 

  12. Lima J, Teixeira-Gomes J, Soares P, Máximo V, Honavar M, Williams D, Sobrinho-Simões M: Germline succinate dehydrogenase subunit D mutation segregating with familial non-RET C cell hyperplasia. J Clin Endocrinol Metab. 2003, 88 (10): 4932-10.1210/jc.2002-030008.

    Article  CAS  PubMed  Google Scholar 

  13. Clayton DA, Doda JN, Friedberg EC: The absence of a pyrimidine dimer repair mechanism in mammalian mitochondria. Proc Natl Acad Sci. 1974, 71 (7): 2777-10.1073/pnas.71.7.2777.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. LeDoux SP, Wilson GL, Beecham EJ, Stevnsner T, Wassermann K, Bohr VA: Repair of mitochondrial DNA after various types of DNA damage in Chinese hamster ovary cells. Carcinogenesis. 1992, 13 (11): 1967-10.1093/carcin/13.11.1967.

    Article  CAS  PubMed  Google Scholar 

  15. Croteau DL, Bohr VA: Repair of oxidative damage to nuclear and mitochondrial DNA in mammalian cells. J Biol Chem. 1997, 272 (41): 25409-25412. 10.1074/jbc.272.41.25409.

    Article  CAS  PubMed  Google Scholar 

  16. Dai JG, Xiao YB, Min JX, Zhang GQ, Yao K, Zhou RJ: Mitochondrial DNA 4977 BP deletion mutations in lung carcinoma. Indian J Cancer. 2006, 43 (1): 20-10.4103/0019-509X.25771.

    Article  PubMed  Google Scholar 

  17. Ye C, Shu XO, Wen W, Pierce L, Courtney R, Gao YT, Zheng W, Cai Q: Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast diseases. Breast Cancer Res Treat. 2008, 108 (3): 427-434. 10.1007/s10549-007-9613-9.

    Article  CAS  PubMed  Google Scholar 

  18. Futyma K, Putowski L, Cybulski M, Miotla P, Rechberger T, Semczuk A: The prevalence of mtDNA4977 deletion in primary human endometrial carcinomas and matched control samples. Oncol Rep. 2008, 20 (3): 683-688.

    CAS  PubMed  Google Scholar 

  19. Akouchekian M, Houshmand M, Hemati S, Ansaripour M, Shafa M: High rate of mutation in mitochondrial DNA displacement loop region in human colorectal cancer. Dis Colon Rectum. 2009, 52 (3): 526-10.1007/DCR.0b013e31819acb99.

    Article  PubMed  Google Scholar 

  20. WADA T, TANJI N, OZAWA A, WANG J, SHIMAMOTO K, SAKAYAMA K, YOKOYAMA M: Mitochondrial DNA mutations and 8-hydroxy-2′-deoxyguanosine Content in Japanese patients with urinary bladder and renal cancers. Anticancer Res. 2006, 26 (5A): 3403-

    CAS  PubMed  Google Scholar 

  21. Fliss MS, Usadel H, Caballero OL, Wu L, Buta MR, Eleff SM, Jen J, Sidransky D: Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science. 2000, 287 (5460): 2017-10.1126/science.287.5460.2017.

    Article  CAS  PubMed  Google Scholar 

  22. Liu VWS, Wang Y, Yang HJ, Tsang PCK, Ng TY, Wong LC, Nagley P, Ngan H: Mitochondrial DNA variant 16189 T > C is associated with susceptibility to endometrial cancer. Hum Mutat. 2003, 22 (2): 173-174. 10.1002/humu.10244.

    Article  CAS  PubMed  Google Scholar 

  23. Poulton J, Luan JA, Macaulay V, Hennings S, Mitchell J, Wareham NJ: Type 2 diabetes is associated with a common mitochondrial variant: evidence from a population-based case–control study. Hum Mol Genet. 2002, 11 (13): 1581-1583. 10.1093/hmg/11.13.1581.

    Article  CAS  PubMed  Google Scholar 

  24. Chinnery P, Elliott H, Patel S, Lambert C, Keers S, Durham S, McCarthy M, Hitman G, Hattersley A, Walker M: Role of the mitochondrial DNA 16184–16193 poly-C tract in type 2 diabetes. Lancet. 2005, 366 (9497): 1650-1651. 10.1016/S0140-6736(05)67492-2.

    Article  CAS  PubMed  Google Scholar 

  25. Ashtiani ZO, Heidari M, Hasheminasab S-M, Ayati M, Rakhshani N: Mitochondrial D-Loop polymorphism and microsatellite instability in prostate cancer and benign hyperplasia patients. Asian Pac J Cancer Prev. 2012, 13: 3863-3868. 10.7314/APJCP.2012.13.8.3863.

    Article  PubMed  Google Scholar 

  26. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Klöppel G, Yoshimura A, Reindl W, Sipos B, Akira S: Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011, 19 (4): 456-469. 10.1016/j.ccr.2011.03.009.

    Article  CAS  PubMed  Google Scholar 

  27. Czarnecka AM, Klemba A, Semczuk A, Plak K, Marzec B, Krawczyk T, Kofler B, Golik P, Bartnik E: Common mitochondrial polymorphisms as risk factor for endometrial cancer. Int Arch Med. 2009, 2 (1): 33-10.1186/1755-7682-2-33.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Rahmani B, Azimi C, Omranipour R, Raoofian R, Zendehdel K, Saee-Rad S, Heidari M: Mutation screening in the mitochondrial D-loop region of tumoral and non-tumoral breast cancer in Iranian patients. Acta Med Iran. 2012, 50 (7): 447-453.

    CAS  PubMed  Google Scholar 

  29. Rosson D, Keshgegian AA: Frequent mutations in the mitochondrial control region DNA in breast tissue. Cancer Lett. 2004, 215 (1): 89-94. 10.1016/j.canlet.2004.04.030.

    Article  CAS  PubMed  Google Scholar 

  30. Seyedhassani SM, Houshmand M, Kalantar SM, Modabber G, Aflatoonian A: No mitochondrial DNA deletions but more D-loop point mutations in repeated pregnancy loss. J Assist Reprod Genet. 2010, 27 (11): 641-648. 10.1007/s10815-010-9435-2.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Mueller EE, Schaier E, Brunner SM, Eder W, Mayr JA, Egger SF, Nischler C, Oberkofler H, Reitsamer HA, Patsch W: Mitochondrial haplogroups and control region polymorphisms in age-related macular degeneration: a case–control study. PLoS One. 2012, 7 (2): e30874-10.1371/journal.pone.0030874.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Zhang J, Asin-Cayuela J, Fish J, Michikawa Y, Bonafé M, Olivieri F, Passarino G, De Benedictis G, Franceschi C, Attardi G: Strikingly higher frequency in centenarians and twins of mtDNA mutation causing remodeling of replication origin in leukocytes. Proc Natl Acad Sci. 2003, 100 (3): 1116-10.1073/pnas.242719399.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Kamalidehghan B, Houshmand M, Panahi MSS, Abbaszadegan MR, Ismail P, Shiroudi MB: Tumoral Cell mtDNA 8.9 kb deletion is more common than other deletions in gastric cancer. Arch Med Res. 2006, 37 (7): 848-853. 10.1016/j.arcmed.2006.03.007.

    Article  CAS  PubMed  Google Scholar 

  34. Kamalidehghan B, Houshmand M, Ismail P, Panahi MSS, Akbari MHH: ΔmtDNA < sup > 4977</sup > is more common in non-tumoral cells from gastric cancer sample. Arch Med Res. 2006, 37 (6): 730-735. 10.1016/j.arcmed.2006.02.005.

    Article  CAS  PubMed  Google Scholar 

  35. Marchington D, Hartshorne G, Barlow D, Poulton J: Homopolymeric tract heteroplasmy in mtDNA from tissues and single oocytes: support for a genetic bottleneck. Am J Hum Genet. 1997, 60 (2): 408-

    PubMed Central  CAS  PubMed  Google Scholar 

  36. Sanchez-Cespedes M, Parrella P, Nomoto S, Cohen D, Xiao Y, Esteller M, Jeronimo C, Jordan RCK, Nicol T, Koch WM: Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. Cancer Res. 2001, 61 (19): 7015-

    CAS  PubMed  Google Scholar 

  37. Schwartz S, Alazzouzi H, Perucho M: Mutational dynamics in human tumors confirm the neutral intrinsic instability of the mitochondrial D‒loop poly‒cytidine repeat. Genes Chromosomes Cancer. 2006, 45 (8): 770-780. 10.1002/gcc.20340.

    Article  CAS  PubMed  Google Scholar 

  38. Dakubo GD: Mitochondrial Genetics and Cancer. 2010, Heidelberg Dordrecht London New York: Springer, 14-123.

    Book  Google Scholar 

  39. Lievre A, Blons H, Houllier A, Laccourreye O, Brasnu D, Beaune P, Laurent-Puig P: Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma. Br J Cancer. 2006, 94 (5): 692-697.

    PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are thankful to the “Urology and Nephrology Research Center (UNRC) of Tehran” for giving the grant for this project and the “National Institute for Genetic Engineering and Biotechnology (NIGEB) of Tehran”, Project 187.

Author information

Authors and Affiliations

  1. Urology and Nephrology Research Center (UNRC), Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Nasser Shakhssalim & Reza Sarhangnejad

  2. National Institute for Genetic Engineering and Biotechnology, Tehran, Iran

    Massoud Houshmand

  3. Department of Pharmacy, Faculty of Medicine, University of Malaya (UM), Kuala Lumpur, 50603, Malaysia

    Behnam Kamalidehghan & Mohammad Hossein Sanati

  4. Medical Genetics Department, Special Medical Center, Tehran, Iran

    Massoud Houshmand, Abolfazl Faraji, Sepideh Dadgar & Maryam Mobaraki

  5. UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, UPM Serdang, Selangor, 43400, Malaysia

    Rozita Rosli

Authors
  1. Nasser Shakhssalim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Massoud Houshmand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Behnam Kamalidehghan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abolfazl Faraji
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Reza Sarhangnejad
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sepideh Dadgar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maryam Mobaraki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rozita Rosli
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mohammad Hossein Sanati
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massoud Houshmand.

Additional information

Authors’ contributions

NS, AF, SD, MM and RS carried out the experimental procedures. BK and RR wrote and edited the manuscript and performed the statistical analysis. MH conceived the project and supervised the study. All authors read and approved the final manuscript.

Authors’ original submitted files for images

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Shakhssalim, N., Houshmand, M., Kamalidehghan, B. et al. The mitochondrial C16069T polymorphism, not mitochondrial D310 (D-loop) mononucleotide sequence variations, is associated with bladder cancer. Cancer Cell Int 13, 120 (2013). https://doi.org/10.1186/1475-2867-13-120

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/1475-2867-13-120

Keywords

Cancer Cell International

ISSN: 1475-2867

Contact us